PMID- 26298725
OWN - NLM
STAT- MEDLINE
DCOM- 20170207
LR  - 20181113
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 37
IP  - 1
DP  - 2016 Jan
TI  - Overexpression of TRIP6 promotes tumor proliferation and reverses cell 
      adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) 
      expression in non-Hodgkin's lymphoma.
PG  - 1369-78
LID - 10.1007/s13277-015-3939-4 [doi]
AB  - Recent studies have identified that thyroid hormone receptor-interacting protein 
      6 (TRIP6) is implicated in tumorigenesis. However, the functional role of TRIP6 
      in non-Hodgkin's lymphoma (NHL) has never been elucidated. In this study, we 
      demonstrated that TRIP6 is reversely correlated with the clinical outcomes of NHL 
      patients. Western blot and immunohistochemical analysis revealed that TRIP6 
      expression is lower in indolent lymphoma than in progressive lymphoma. 
      Kaplan-Meier survival curves indicated that the upregulation of TRIP6 is 
      significantly associated with poor overall survival. Moreover, patients with 
      higher expression of TRIP6 are prone to shorter time to recurrence. Furthermore, 
      we also found that TRIP6 can promote the proliferation of NHL cells via 
      regulating cell cycle progression. In addition, adhesion of lymphoma cells to 
      fibronectin (FN) decreased TRIP6 expression, which led to the upregulation of 
      nuclear p27(Kip1) expression by decreasing phosphorylation of p27(Kip1) at T157. 
      Importantly, overexpression of TRIP6 can reverse cell adhesion-mediated drug 
      resistance (CAM-DR) phenotype in NHL. In summary, these results suggest that 
      TRIP6 is a novel prognostic indicator for NHL patients and may shed new insights 
      into the important role of TRIP6 in cancer development.
FAU - Miao, Xiaobing
AU  - Miao X
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Xu, Xiaohong
AU  - Xu X
AD  - Department of Oncology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Wu, Yaxun
AU  - Wu Y
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Zhu, Xinghua
AU  - Zhu X
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Chen, Xudong
AU  - Chen X
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Li, Chunsun
AU  - Li C
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Lu, Xiaoyun
AU  - Lu X
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Chen, Yali
AU  - Chen Y
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Liu, Yushan
AU  - Liu Y
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Huang, Jieyu
AU  - Huang J
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China.
FAU - Wang, Yuchan
AU  - Wang Y
AD  - Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, 
      Nantong University, Nantong, 226001, Jiangsu, China. wangyuchannt@126.com.
FAU - He, Song
AU  - He S
AD  - Department of Pathology, Affiliated Cancer Hospital of Nantong University, 
      Nantong, 226361, Jiangsu, China. hesongnt@126.com.
LA  - eng
PT  - Journal Article
DEP - 20150823
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (Adaptor Proteins, Signal Transducing)
RN  - 0 (CDKN1B protein, human)
RN  - 0 (LIM Domain Proteins)
RN  - 0 (PSMC5 protein, human)
RN  - 0 (Transcription Factors)
RN  - 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27)
RN  - EC 3.4.25.1 (Proteasome Endopeptidase Complex)
RN  - EC 3.6.4.- (ATPases Associated with Diverse Cellular Activities)
SB  - IM
MH  - ATPases Associated with Diverse Cellular Activities
MH  - Adaptor Proteins, Signal Transducing/*metabolism
MH  - Aged
MH  - Cell Adhesion
MH  - Cell Cycle
MH  - Cell Proliferation
MH  - Cell Survival
MH  - Cyclin-Dependent Kinase Inhibitor p27/*metabolism
MH  - *Drug Resistance, Neoplasm
MH  - Female
MH  - Flow Cytometry
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - LIM Domain Proteins/*metabolism
MH  - Lymphoma, Non-Hodgkin/*metabolism
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Phenotype
MH  - Prognosis
MH  - Proteasome Endopeptidase Complex
MH  - Transcription Factors/*metabolism
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cell adhesion-mediated drug resistance (CAM-DR)
OT  - Non-Hodgkin's lymphoma (NHL)
OT  - Proliferation
OT  - TRIP6
OT  - p27Kip1
EDAT- 2015/08/25 06:00
MHDA- 2017/02/09 06:00
CRDT- 2015/08/24 06:00
PHST- 2015/06/28 00:00 [received]
PHST- 2015/08/17 00:00 [accepted]
PHST- 2015/08/24 06:00 [entrez]
PHST- 2015/08/25 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
AID - 10.1007/s13277-015-3939-4 [pii]
AID - 10.1007/s13277-015-3939-4 [doi]
PST - ppublish
SO  - Tumour Biol. 2016 Jan;37(1):1369-78. doi: 10.1007/s13277-015-3939-4. Epub 2015 
      Aug 23.